View Financial HealthAlterola Biotech 配当と自社株買い配当金 基準チェック /06Alterola Biotech配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 30+ 2 more updatesAlterola Biotech, Inc. Announces Resignation of Nathan Thompson as Chief Financial OfficerAlterola Biotech, Inc. announced that On May 16, 2025 Nathan Thompson resigned as Chief Financial Officer.お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2025, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 29Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/28/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 18Alterola Biotech, Inc. Announces Executive ChangesAlterola Biotech, Inc. appointed Nathan Thompson as a member of Board of Directors. Nathan Thompson has been Chief Financial Officer of United Science LLC (“United”) since April of 2016, and previously served as Vice President of Operations from April of 2016 to May 2019. Prior to his employment with United, Mr. Thompson served as Corporate Accounting Manager of Link Snacks, Inc. from April 2008 to March 2016. Mr. Thompson also gained audit experience from September 2001 to April 2008 working as a Senior Internal Auditor for ALLETE, Inc. Mr. Thompson brings over 20 years of executive accounting experience to the Board. Mr. Thompson does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940. There are no family relationships between Mr. Thompson and any of directors or executive officers. Mr. Thompson has not had any material direct or indirect interest in any of the Company’s transactions or proposed transactions over the last two years. Also, as a consequence of the expired option for Bright Green Corporation to acquire Alterola and the lack of success of the parties to reach a new agreement, Mr. Terry Rafih, who was appointed in connection with the potential acquisition, is no longer a member of Board of Directors. On October 13, 2023, the company replaced Messrs. Brendan McAleer and Duncan Boxwell with Mr. Hunter Land to serve on the audit committee of company. The committee is now comprised of Ning Qu as Chairperson and Mr. Land, both independent directors of company.お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/15/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 30Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.New Risk • Jun 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.07m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$8.07m market cap).お知らせ • Nov 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 08+ 1 more updateAlterola Biotech, Inc. Executive ChangesOn October 3rd, 2022, Alterola Biotech, Inc. announced Seamus McAuley resigned as Chief Executive Officer, with immediate effect. On October 7, 2022, the board of directors accepted the resignation of Seamus McAuley as Chief Executive Officer. Also on October 7, 2022, the company David Hitchcock was appointed as CEO. David Hitchcock, OBE has worked in the City of London for nearly 30 years, most recently in companies he co-founded to facilitate equity investment into UK Small and Medium Enterprises (SMEs). His experience concentrated particularly in the UK Life Sciences and Precision Engineering Sectors including listings onto the London Stock Exchange. David and his team bought several high precision engineering companies from administration, turning them round and creating over 200 jobs in Wales and the West of England including a standalone apprentice training centre. David spent 21 years in Investment Banking with 10 years as a Managing Director at JPMorgan and Head of Investor Client Management. David and his team managed the bank’s most senior client relationships with its most important institutional asset managers and hedge funds in the UK and EMEA. He began his City career in Equities at Goldman Sachs in 1992. Before entering the City David served as a British Army Officer with The Sixth (Queen Elizabeth’s Own) Gurkha Rifles. He is a Graduate of The Royal Military Academy, Sandhurst and Pembroke College, Cambridge. David has lectured at The Royal College of Defence Studies and the Master of Finance Course at the Judge Business School, Cambridge University. He is a Trustee of several educational and military charities.お知らせ • Oct 05Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI).Bright Green Corporation (NasdaqCM:BGXX) has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) for $4 million on August 25, 2022. Bright Green will initially purchase 25% of the issued and outstanding common stock of Alterola for total consideration of $4 million and will receive a 6 month option to purchase Alterola’s remaining issued and outstanding common stock for an additional $6 million and approximately $40 million in Bright Green common stock. Terry Rafih, or his designee, shall be appointed to Alterola’s Board of Directors. The transaction is subject to completion of initial satisfactory due diligence, Bright Green shall have obtained and completed sufficient and satisfactory financing of the Purchase Price, other customary conditions and closing of the additional proposed arrangement, which will be set forth in a final definitive agreement. The transaction is expected to close in the second half of 2022. Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) on October 4, 2022.お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.決済の安定と成長配当データの取得安定した配当: ABTIの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ABTIの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Alterola Biotech 配当利回り対市場ABTI 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ABTI)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (ABTI) (最長3年)n/a注目すべき配当: ABTIは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ABTIは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ABTIの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ABTIが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 22:05終値2026/02/23 00:00収益2024/09/30年間収益2024/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Alterola Biotech, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 30+ 2 more updatesAlterola Biotech, Inc. Announces Resignation of Nathan Thompson as Chief Financial OfficerAlterola Biotech, Inc. announced that On May 16, 2025 Nathan Thompson resigned as Chief Financial Officer.
お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2025, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 29Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/28/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/14/2024, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/14/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 18Alterola Biotech, Inc. Announces Executive ChangesAlterola Biotech, Inc. appointed Nathan Thompson as a member of Board of Directors. Nathan Thompson has been Chief Financial Officer of United Science LLC (“United”) since April of 2016, and previously served as Vice President of Operations from April of 2016 to May 2019. Prior to his employment with United, Mr. Thompson served as Corporate Accounting Manager of Link Snacks, Inc. from April 2008 to March 2016. Mr. Thompson also gained audit experience from September 2001 to April 2008 working as a Senior Internal Auditor for ALLETE, Inc. Mr. Thompson brings over 20 years of executive accounting experience to the Board. Mr. Thompson does not hold and has not held over the past five years any other directorships in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of the Exchange Act or any company registered as an investment company under the Investment Company Act of 1940. There are no family relationships between Mr. Thompson and any of directors or executive officers. Mr. Thompson has not had any material direct or indirect interest in any of the Company’s transactions or proposed transactions over the last two years. Also, as a consequence of the expired option for Bright Green Corporation to acquire Alterola and the lack of success of the parties to reach a new agreement, Mr. Terry Rafih, who was appointed in connection with the potential acquisition, is no longer a member of Board of Directors. On October 13, 2023, the company replaced Messrs. Brendan McAleer and Duncan Boxwell with Mr. Hunter Land to serve on the audit committee of company. The committee is now comprised of Ning Qu as Chairperson and Mr. Land, both independent directors of company.
お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/15/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 30Alterola Biotech, Inc. announced delayed annual 10-K filingOn 06/29/2023, Alterola Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
New Risk • Jun 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$8.07m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (US$8.07m market cap).
お知らせ • Nov 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 11/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 08+ 1 more updateAlterola Biotech, Inc. Executive ChangesOn October 3rd, 2022, Alterola Biotech, Inc. announced Seamus McAuley resigned as Chief Executive Officer, with immediate effect. On October 7, 2022, the board of directors accepted the resignation of Seamus McAuley as Chief Executive Officer. Also on October 7, 2022, the company David Hitchcock was appointed as CEO. David Hitchcock, OBE has worked in the City of London for nearly 30 years, most recently in companies he co-founded to facilitate equity investment into UK Small and Medium Enterprises (SMEs). His experience concentrated particularly in the UK Life Sciences and Precision Engineering Sectors including listings onto the London Stock Exchange. David and his team bought several high precision engineering companies from administration, turning them round and creating over 200 jobs in Wales and the West of England including a standalone apprentice training centre. David spent 21 years in Investment Banking with 10 years as a Managing Director at JPMorgan and Head of Investor Client Management. David and his team managed the bank’s most senior client relationships with its most important institutional asset managers and hedge funds in the UK and EMEA. He began his City career in Equities at Goldman Sachs in 1992. Before entering the City David served as a British Army Officer with The Sixth (Queen Elizabeth’s Own) Gurkha Rifles. He is a Graduate of The Royal Military Academy, Sandhurst and Pembroke College, Cambridge. David has lectured at The Royal College of Defence Studies and the Master of Finance Course at the Judge Business School, Cambridge University. He is a Trustee of several educational and military charities.
お知らせ • Oct 05Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI).Bright Green Corporation (NasdaqCM:BGXX) has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) for $4 million on August 25, 2022. Bright Green will initially purchase 25% of the issued and outstanding common stock of Alterola for total consideration of $4 million and will receive a 6 month option to purchase Alterola’s remaining issued and outstanding common stock for an additional $6 million and approximately $40 million in Bright Green common stock. Terry Rafih, or his designee, shall be appointed to Alterola’s Board of Directors. The transaction is subject to completion of initial satisfactory due diligence, Bright Green shall have obtained and completed sufficient and satisfactory financing of the Purchase Price, other customary conditions and closing of the additional proposed arrangement, which will be set forth in a final definitive agreement. The transaction is expected to close in the second half of 2022. Bright Green Corporation (NasdaqCM:BGXX) completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) on October 4, 2022.
お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 16Alterola Biotech, Inc. announced delayed 10-Q filingOn 02/15/2022, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 17Alterola Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Alterola Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.